University of Rhode Island

DigitalCommons@URI
Open Access Master's Theses
1998

LIDOCAINE METABOLISM IN ENDOTOXIN INDUCED SEPSIS
Judah Boulet
University of Rhode Island

Follow this and additional works at: https://digitalcommons.uri.edu/theses

Recommended Citation
Boulet, Judah, "LIDOCAINE METABOLISM IN ENDOTOXIN INDUCED SEPSIS" (1998). Open Access
Master's Theses. Paper 238.
https://digitalcommons.uri.edu/theses/238

This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information,
please contact digitalcommons@etal.uri.edu.

LIDOCAINE METABOLISM IN ENDOTOXIN INDUCED SEPSIS
BY
JUDAH BOULET

A THESIS SUBMITTED IN PARTIAL FUFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN
PHARMACOLOGY AND TOXICOLOGY

UNIVERSITY OF RHODE ISLAND
1998

MASTER OF SCIENCE THESIS
OF
JUDAH A. BOULET

APPROVED:

~ / ] / ,/

Thesis Committee

/1

Major Professor

~~

DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
1998

Abstract
Septic shock is the body' s inflammatory response to an infection, and is usually
associated with gram negative bacteria. It is characterized by hypotension and
hypoperfusion, despite adequate fluid resuscitation, and can lead to multiple organ
failure. At these advanced stages there is a high morbidity and mortality rate associated
with it. One mediator of this inflammatory response is a lipopolysaccharide (LPS), or
endotoxin, found in the gram negative bacterial cell wall.
Besides having effects on the body as a whole, there are many cellular processes
affected by endotoxin. In the body, there is a family of enzymes, the cytochrome P450
enzymes, which are the body's drug metabolizing enzymes. Although found in all tissue
types, the P450 enzymes are mainly located in the liver. There are many families and
isoforms of these enzymes, of which several are inhibited by endotoxin. The regulation of
the P450 enzymes is very complex. During the systemic inflammatory response to
endotoxin, many cytokine mediators are released into the bloodstream. These mediators,
specifically tumor necrosis factor-a, interleukin-I , and interleukin-6, all are capable of
regulating the activity, and production of the P450 enzyme system.
Lidocaine is a widely used antiarrhythmic drug, which is metabolized by
cytochrome P450 enzymes, to its major metabolite monoethylglycinexylidide (MEGX).
Lidocaine is metabolized specifically by P450 3A2, 2Cl 1, and 2B 1 in the rat. The
conversion of lidocaine to MEGX has been looked at as a method of evaluating liver
function or dysfunction in a variety of liver related diseases, including viral hepatitis,
cirrhosis, liver transplantation, and hypovolemic shock.
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This present study was undertaken to determine whether the conversion of
lidocaine to MEGX was inhibited in vivo, in rats given a lethal dose of endotoxin. It was
hoped that the degree of drug metabolizing inhibition could be determined using this
whole animal model, since many of the systemic effects of septic shock, i.e. hypotension,
also factor into the clearance of a high extraction compound, like lidocaine. Results from
this study could potentially be helpful in determining drug metabolizing alterations in
humans experiencing septic shock.
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Abstract
Gram-negative bacterial endotoxin causes a systemic inflammatory
response, known as sepsis. High exposure to endotoxin can lead to septic shock, which is
characterized by hypoperfusion and hypotension, which can ultimately lead to multiple
organ failure, and death. One of the organs highly effected by endotoxin is the liver. The
liver has a family of enzymes, the cytochrome P450 enzymes, which handle the
biotransformation of many xenobiotics, to excretable compounds. Endotoxin inhibits this
biotransformation by inhibiting and down regulating many P450 isoforms. This paper
describes a study into the metabolism of lidocaine during a endotoxin induced shock.
Lidocaine is metabolized via P450 enzymes, to MEGX, the major metabolite. Serum
concentrations of lidocaine and MEGX were analyzed at various time points. Blood
pressure measurements were also taken to determine if hypotension played any role in
reduced lidocaine clearance.
A lethal dose of endotoxin caused severe hypotension eight hours after
administration (mean±SEM; 51. 7±50. 7) when compared to control animals (mean±SEM;
108±9. 5). Endotoxin significantly inhibited the clearance of lidocaine in vivo at 120
minutes (mean±SEM: 1.16±0.52) when compared to control animals (mean±SEM;
0.08±0.067) (p<0.05). The degree of inhibition was greater than cimetidine treated
animals (mean±SEM; 0.15±0.073) though, which is a positive control for P450
inhibition, suggesting that the reduc5ion of blood pressure could possibly be a factor in
the clearance (p<0.05). The serum level MEGX was elevated in the endotoxin treated
animals (mean±SEM; 626.8±123 .2) compared to control (mean±SEM; 137.5±44.2) and
cimetidine animals (mean± l6 l.1±71. l) at 120 minutes (p<0.05). It is possible that the

elevated concentration of metabolite in the serum of septic animals is the result of
reduced clearance of metabolites secondary to blood flow in the kidneys, and/or reduced
bile flow . Since the serum MEGX did not appear to reflect the decreased lidocaine
clearance, ratios of lidocaine:MEGX were calculated. A significant difference between
the endotoxin treated and cimetidine treated groups was seen at 15 minutes was seen
(p<0.05). The ratio of lidocaine:MEGX appears to be a potential measure of inhibition of
drug metabolism, but further exploration in this model is needed.
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Introduction

Lidocaine, is the most widely used intravenous anti-arrhythmic agent for the
management of acute ventricular arrhythmias. (Zito, et. al., 1978) Lidocaine is totally
and rapidly metabolized in the liver, (Bennet, et. al. , 1982; Keenaghamp, et. al., 1972)
with one of its major metabolites produced by oxidative N-deethylation to
monoethylglycinexylidide (MEGX). (Nyberg, et. al., 1977) It has been postulated that
the conversion of lidocaine to MEGX be used as a marker of liver function and drug
metabolism during different disease states. It has been shown that after administration of
lidocaine, serum MEGX levels at 15 minutes is a sensitive and specific indicator of
hepatic damage, (Berdelski, et. al., 1987; Oellerich, et. al. , 1987) compared to
indocyanine green and galactose. (Burdelski, et. al., 1988) Lidocaine and its metabolism
has been suggested as a way to monitor pre-transplant liver function (Oellerich, et. al. ,
1987; Schroeder, et. al., 1989) and as an early predictor of rejection in transplant
recipients. (Schroeder, et. al. , 1989) MEGX formation can also be used for the rapid
assessment of liver function in cirrhosis, (Oellerich, et. al. , 1990) and after hypovolemic
shock. (Chandel, et. al. , 1995)
Sepsis is the developed condition of the body's systemic inflammatory response
to the presence of an infection in the body by a microorganism, most frequently derived
from gram-negative bacteria. When sepsis further deteriorates, septic shock can result.
Shock is frequently associated with poor circulation, hypotension and hypoperfusion, and
can lead to multiple organ failure. A number of studies have shown that there is severe
liver dysfunction following sepsis. (Wang, et. al. , 1995 ; Wang, et. al. , 1991) Hepatic
function and effective hepatic blood flow, as measured by clearance of indocyanine
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green, was decreased in studies using the cecal ligation and puncture septic animal
model. (Wang, et. al., 1991; Wang, et. al., 1995) The activity of the cytochrome P450
drug metabolizing enzyme system also changes in sepsis. It has been shown in rats and
mice, that after endotoxin administration, P450 2B l (Stanley, et. al., 1988), 2Cl l
(Morgan, 1989; Sewer, et. al., 1996; Morgan, 1993), 2C 12 (Morgan, 1993), 2C6
(Morgan, 1993), 2C7 (Morgan, 1993), 3A2 (Sewer et. al., 1996) and 2El(Morgan, 1993;
Sewer et. al., 1996) are suppressed.(Ishikawa, et. al., 1991) Also, it has been shown that
there is a significant decrease in drug metabolism in human subjects exposed to
significantly smaller dose of endotoxin than would be expected in a clinical case of
septic shock. (Shedlofsky, et. al., 1996)
Systemically, endotoxin has profound effects on the heart, other organs and the
vasculature, with a major cause of morbidity associated with a hypotensive state, which
persists despite adequate fluid resuscitation. (Parillo, et. al., 1993) Endotoxin also
inhibits P450 activity, including the enzymes that metabolize lidocaine, P4502B 1,
P4502Cl 1, and P4503A2, which have the highest MEGX formation turnover in the rat.
(Oda, et. al., 1989; Imaoka, et. al., 1990; Nakamoto, et. al., 1997) Although it has been
shown that endotoxin inhibits these P450 isoforms, and that these isoforms are
responsible for the metabolism of lidocaine to MEGX, lidocaine metabolism during
septic shock has not been studied. Since MEGX formation has been considered as a
model for liver dysfunction in cirrhosis (Oellerich et. al ., 1990), hypovolemic shock
(Chandel, et. al., 1995) liver transplantation (Oellerich et. al., 1989; Schroeder et. al.
1989), ischemic liver injury (LeClercq, et. al, 1997) and chronic viral hepatitis (Elin, et.
al., 1997), we examined if MEGX formation was a good marker for the metabolic
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changes induced by endotoxin. It is thus needed to examine the metabolism of lidocaine
to MEGX in the in vivo animal model, where the blood pressure, and subsequent liver
blood flow are dramatically different between septic and control animals.
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Materials and Methods
Experimental protocols were approved by the Institutional Animal Care and Use
Committee of the University of Rhode Island. All reagents were purchased from Sigma
Chemical, with the exception of the lipopolysaccharide, purchased from Difeo
Laboratories, and the TDx analyzer kits, which were graciously supplied by Abbott
Laboratories.
Male Sprague Dawley rats, ranging from 250-550g, were administered endotoxin
or cimetidine. Endotoxin (E. Coli 026 :B6 LPS, lot #91608), 45.6 mg/kg, was injected IP
approximately 5 hours before surgery. Cimetidine, 80mg/kg, was injected IP daily for
three days prior to surgery. This group served as a positive control for inhibition of
cytochrome P450 (Levine, et. al., 1998; Bruck, et. al. , 1990; Froncillo, et. al. , 1983)
Initial blood pressure readings and lidocaine administration occurred at six hours after
endotoxin injection, which was 24 hours after the third cimetidine injection.

In Vi vo Study of Blood Pressure
Rats, weighing 250-550 g, were anaesthetized with pentobarbital (50 mg/kg) . A
mid-line incision from the chin to the upper part of the thorax was made so that both the
trachea and left carotid artery could be cannulated. A short cannula was secured in the
trachea, while a cannula, filled with a 10 units/ml heparin/saline solution, attached to a 1
mL syringe, was secured into the artery. An infusion of 0.4 mL of the heparin/saline
solution was made, and the rat was allowed to stabilize for 30 minutes. After the rat had
stabilized, blood pressure recordings were taken at 0, 60, 90, and 120 minutes using a
Statham P-23A transducer, and recorded on a Grass Model 7 Polygraph.
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In Vivo study of Lidocaine Metabolism

Lidocaine (2mg/kg) was administered via the cannula at time zero . The catheter
was then flushed with 0.3 m.L of saline. Blood, 0.4 m.L, was drawn via the cannula at
times 15, 25, 45, 60, 90, and 120 minutes, and centrifuged at 3,000 x g for 3-5 minutes to
collect the serum. After each blood withdrawal, the animal was infused with the same
amount of saline to make up for fluid loss. Serum samples were analyzed for lidocaine
and its major metabolite monoethylglycinexylidide (MEGX) using a fluorescence
immunoassay (TDx). (Abbott Diagnostics, Abbott Park, Illinois) The standard curve was
linear between 0 and 10 µg/m.L for lidocaine, and 0-250 ng/mL for MEGX. Coefficients
of variation for each of these assays were 10% at all control concentrations.

Statistical Analysis

Repeated measures ANOVA was used to compare blood pressure data. After a
significant overall difference was found , a Student-Newman-Keuls method was used as
the pairwise multiple comparison procedure. All lidocaine and MEGX data was tested
with a one-way ANOVA, and after a significant difference was found , a Tukey ' s multicomparison post hoc test was used. Significance was determined by a p value of <0.05.
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Results
Endotoxin had a detrimental effect on the blood pressure. (Figure l) There was a
significant decrease in blood pressure between the endotoxin and the control groups at 90
and 120 minutes (p<0.05) and between the endotoxin and the cimetidine groups at 90 and
120 minutes (p<0.05). The average blood pressure of the endotoxin group dropped from
105±23 .5 mmHg, at time zero, to 51.7±50.7 mmHg two hours later, while the blood
pressures of the untreated and cimetidine group stayed constant throughout the
experiment. The average blood pressure at eight hours after endotoxin administration
decreased by approximately 50% of the untreated and cimetidine groups. The blood
pressures of the endotoxin group at 60, 90, and 120 minutes were significantly lower than
the blood pressures at time zero (p<0.05). After examination of blood pressure data of
the endotoxin group, two sub-populations of endotoxin treated rats were distinguished ;
those that showed a drop in blood pressure (n=4), and those that were unaffected (n=3).
(Figure 2) These two groups were significantly different at time points 90, and 120
minutes (p<0.05). The animals whose blood pressure dropped were significantly
different versus the control group at 90 and 120 minutes (p<0.05).
Lidocaine elimination was significantly lower than the untreated and cimetidine
groups at 120 minutes after administration (p<0.05). (Figure 3) At 120 minutes after
lidocaine administration, the endotoxin group had a 14.5 fold and 7.5 fold higher
concentration of lidocaine than the untreated and cimetidine groups, respectively. The
cimetidine group had a 1.9 fold greater lidocaine concentration than the untreated group.
MEGX concentrations were determined at the same time points as lidocaine.
(Figure 4) MEGX serum levels increased during the first 60 minutes after lidocaine

administration and then began to plateau for the last 60 minutes of the experiment in the
control groups, while in the endotoxin group, MEGX concentrations continued to
increase throughout the experiment. The concentrations in the endotoxin group were
significantly higher than control and cimetidine groups at all time points except 15
minutes (p<0.05). The endotoxin group had a 3.4 fold greater concentration ofMEGX
than the untreated group, and a 2.9 fold higher level than the cimetidine, at 120 minutes
after lidocaine administration. The cimetidine group had a slightly higher serum level of
ivIBGX than the untreated group, but the average difference in concentration between the
two groups was approximately 24 ng/mL, and was found insignificant.
Lidocaine:ivIBGX ratios were derived to normalize the effects of endotoxin on the
changes of lidocaine concentration on MEGX formation. (Figure 5) At 15 minutes there
was a significant difference between the lidocaine:ivIBGX ratio for the endotoxin group
and the control group(p<0.05). Significant differences were also shown at 15 minutes
between the endotoxin and cimetidine groups (p<0.05), and the cimetidine and control
groups (p<0.05). At later time points, the lidocaine:MEGX ratio of the endotoxin group
at 120 minutes was 5.6 fold higher than the untreated group, and twice that of the
cimetidine group. The cimetidine group had a lidocaine:MEGX ratio that was 2.5 fold
higher than the untreated at the same time point.
In order to examine the effect of blood pressure on the concentration of lidocaine
and MEGX, we divided the endotoxin group into those that had a significant blood
pressure decrease (shock) , and tho~~ that showed no effect on blood pressure (nonshock) . The two groups were examined for changes in MEGX and lidocaine
concentrations. Lidocaine concentrations for the group whose blood pressures dropped
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had a 1.5 fold larger lidocaine serum level at 120 minutes after lidocaine administration,
compared to the group whose blood pressures did not change, but the changes were not
significant at the p<0.05 level. (Figure 6) MEGX levels were significantly higher for
both the shock and non-shock at 45, 60, 90, and 120 minutes compared to control animals
(p<0.05). The non-shock group and the control group were significantly different at 25
minutes (p<0.05). At 120 minutes, average MEGX concentrations were 128% higher for
those that were not in shock compared to those in shock at 120 minutes. (Figure 7) The
ratio of lidocaine:MEGX was approximately twice as great for the shocked compared to
non-shocked animals. (Figure 8) At 15 minutes there was a significant difference
between the shock and non-shock sub-groups (p<0.05) and between the shock and
control group (p<0.05). These data suggest that blood pressure may have an effect on the
clearance of lidocaine and MEGX.

I0

Figure 1. Blood pressures (mmHg) of untreated (n=5), cimetidine (n=5, 80 mg/kg, for

three days), and endotoxin (n=7, 6 hours pre-treatment with endotoxin, LD 100 ) treated
animals, over two hours. The blood pressures were measured on a Stratham polygraph in
mmHg (* p<0.05 LPS vs . Control at 90 and 120 minutes)(+ p<0.05 LPS vs. Cimetidine
at 90 and 120 minutes) (- p<0.05 LPS vs. Time 0 at 90 and 120 minutes). Means± SEM
are reported.

11

100

80
CJ)

I

E
E
60

40

+

---- Untreated
--0- Cimetidine
--...-- Endotoxin
0

20

*+-

40

60

80

Time (Minutes)

12

100

120

140

Figure 2. Blood Pressures (mmHg) of the two sub-populations of endotoxin treated rats

(six hour pre-treatment, LD100), shock (n=4), and non-shock(n=3), over the course of two
hours. Blood pressures are measured in mmHg (* p<0.05 shock vs. non-shock at 90 and
120 minutes)(+ p<0.05 Shock vs. Control at 90 and 120 minutes) (- p<0.05 Shock vs
Time 0 at 60, 90, and 120 minutes). Means± SEM are reported.
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Figure 3. Lidocaine concentrations of untreated (n=5), cimetidine (n=5, 80 mg/kg, for

three days) and endotoxin (n=7, six hour pre-treatment, LD 100 ) groups over a course of
two hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15,
25, 45, 60, 90, and 120 minutes after dosage(* p<0.05 LPS vs. Control at 25, 45,60,90,
and 120 minutes)(+ p<0.05 LPS vs. cimetidine at 45, 60, 90, and 120 minutes). Means±
SEM are reported .
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Figure 4. MEGX concentrations of untreated (n=5), cimetidine (n=5, 80 mg/kg. For three

days) and endotoxin (n=7, six hour pre-treatment, LD100) groups over a course of two
hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 25,
45, 60, 90, and 120 minutes after dosage. Serum samples were assessed for
monoethylglycinexylidide (MEGX), the major metabolite of lidocaine (* p<0.05 LPS vs.
Control at 15, 25,45, 60, 90, and 120 minutes)(+ p<0.05 LPS vs. Cimetidine at 15, 25,
45, 60, 90, 120 minutes). Means± SEM are reported.
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Figure 5. Ratio of Lidocaine:MEGX of untreated (n=5), cimetidine (n=5, 80 mg/kg, for

three days) and endotoxin (n=7, six hour pre-treatment, LD 100) groups over a course of
two hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15,
25, 45, 60, 90, and 120 minutes after dosage(* p<0.05 LPS vs. Cimetidine at 15
minutes). Means± SEM are reported.
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Figure 6. Lidocaine concentrations of the two sub-populations of endotoxin treated rats

(six hour pre-treatment, LD100), shock (n=4), and non-shock (n=3), over the course of two
hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 25, 45,
60, 90, and 120 minutes after dosage(* p<0.05 Shock vs. Control at 45, 60, 90, and 120
minutes)(+ p<0.05 Non-Shock vs. Control at 45, 60, 90, and 120 minutes). Means±
SEM are reported .
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Figure 7. MEGX concentrations of the two sub-populations of endotoxin treated rats

(six hour pre-treatment, LD100), shock (n=4), and non-shock (n=3), over the course of two
hours . Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 25, 45,
60, 90, and 120 minutes after dosage(* p<0.05 Shock vs. Control at 15, 25, 45, 60, 90,
and 120 minutes)(+ p<0.05 Non-shock vs. Control at 15, 25, 45, 60, 90, and 120minutes)
(-p<0.05 Non-shock vs. Shock at 25, 45, 60, and 90 minutes). Means± SEM are
reported.
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Figure 8. Lidocaine/MEGX ratios of the two sub-populations of endotoxin treated rats

(six hour pre-treatment, LD100), shock (n=4), and non-shock (n=3), over the course of two
hours. Lidocaine (2mg/kg) was administered and serum samples were taken at 15, 25, 45,
60, 90, and 120 minutes after dosage(* p<0.05 Shock vs. Control at 15, 60, and 120
minutes)(+ p<0.05 Non-Shock vs. Control at 15 min). Means± SEM are reported .
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Discussion
There was a significant decrease in the blood pressure between the untreated and
endotoxin groups. Many previous models have examined the effects of low dose
endotoxin administration chronically and acutely. (Fish, et. al., 1986; Keeler, et. al. ,
1981; Dedichen, 1972; Suffredini, et. al., 1989) Although these models showed some
effect of low dose endotoxin on hemodynamics, we were interested in the effects of a
100% lethal dose, and the immediate effects on blood pressure. Previous studies in rats
using a low dose of endotoxin, 1 mg/kg/day, elicited insignificant drops in mean arterial
pressures after 6 hours, but after 30 hours of chronic administration there was a
significant change in pressure. (Fish, et. al., 1986) Keeler, et. al. found no significant
change in mean arterial pressure after an acute 4 hour infusion of 2.5 mg/kg/hr endotoxin,
but saw significant changes after a chronic infusion of 2.4-2.9 mg/kg over 4 days.
(Keeler, et. al., 1981) In a canine model, aortic blood pressures dropped between control
and endotoxin animals one hour after endotoxin administration, and continued to fall over
the course of the next six hours. (Dedichen, 1972) Endotoxin response on blood pressure
has been shown to significantly decrease mean arterial pressure after five hours in
humans. (Suffredini, et. al., 1989) Although blood pressure changes occurred in these
previous experiments, the degree of magnitude was less than that seen in this experiment.
This can be attributed to the differences in dosages between experiments, and leads us to
believe that an extremely large

do~~

of endotoxin can cause severe and lethal hypotension

within eight hours after administration.
Two distinguishable sub-populations of endotoxin rats were shown, shocked and
non-shocked. The non-shocked animals had very small decreases in pressure, less than
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20 mmHg, which were comparable to the insignificant acute responses of blood pressure
to endotoxin previously seen. (Fish, et. al. , 1986; Keeler, et. al. , 1981) The shocked
animals had blood pressures so low that life was unsustainable after the eight hours.
The clearance of lidocaine from the serum was reduced in the endotoxic model.
After 20 minutes, the endotoxin group showed very little change in lidocaine
concentrations, compared to the control groups. This reduction in clearance could
possibly be due to alterations in the liver enzymes reducing the rate of lidocaine
metabolism. Lidocaine is metabolized via P4502Cl1, 2Bl, and 3A2 to MEGX in the
rat. (Nakamoto, et. al., 1997; Oda, et. al., 1989; Imaoka, et. al., 1990) In normal rats the
levels of2Cl 1 and 3A2 are 139 and 84 pmol/mg protein, compared to 6.9 pmol/mg
protein for 2B 1. (Nakamoto et. al., 1997) Nakamoto, et. al., showed that upon induction
of liver enzymes with phenobarbital, the rate at which MEGX is formed is increased.
2B 1 levels were increased to 360 pmol/mg protein, and 3A2 levels rose to 390 pmol/mg
protein, while 2C 11 levels stay the same. This suggests that the more 2B 1 and 3A2 there
is in the rat liver, the greater the formation of MEGX in vivo will be. (Nakamoto, et. al. ,
1997) It has been shown in rats that after six and twelve hours, P4502C 11 (Morgan,
1989) and P4503A2 (Sewer, et. al. , 1996) respectively are down regulated after a single
1mg/kg dose of endotoxin. P450 2B 1 was also inhibited in mice by low dose endotoxin
as well. (Stanley, et. al. , 1988) It is known that the systemic response to endotoxin is
expressed by a variety of cytokine mediators. Using a higher dose of endotoxin than used
in. previous experiments, it could b~ assumed that there would be a much larger systemic
response. Upon this assumption one might assume a greater degree of down-regulation
of P450 due to the increase of cytokine mediators, leading to greater inhibition.
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Cimetidine was used as a positive control of P450 inhibition because it has been
shown in rat to inhibit lidocaine clearance in vivo (Fruncillo, et. al., 1983), and in the
perfused liver. (Bruck, et. al., 1990) This inhibition in lidocaine clearance was seen,
however, the resultant decrease in lidocaine clearance was only intermediate to that
shown by endotoxin. The specificity of metabolism of the P450 isoenzymes may explain
the lower lidocaine clearance in the endotoxin animals. Cimetidine has been shown to
inhibit 2Cl 1, but not members of the 2B or 3A family in rats. (Levine, et. al., 1998) In
untreated animals, lidocaine metabolism to its major metabolite, tvffiGX, is dependent on
both 2Cl 1 and 3A2. (Nakamoto, et. al., 1997) Therefore, only one of the two main
isoforms of P450 responsible for lidocaine metabolism is inhibited. Thus, cimetidine
would have less of an effect on lidocaine clearance than during endotoxic shock where
both forms are inhibited. Endotoxin inhibits P450 isoforms responsible for lidocaine
metabolism, but physiologic changes in the hemodynamics also might intensify the
alterations seen.

Hepatic blood flow is an important aspect of lidocaine elimination, and clinical
manifestations that reduce hepatic blood flow would also be expected to rate lidocaine
would be eliminated. (Zito, et. al. , 1978) Indocyanine green (ICG) elimination is
dependent exclusively on hepatic blood flow . (Zito, et. al. , 1978) It has been shown
using a different model of sepsis, cecal ligation and puncture (CLP), that hepatic blood
flow increases at early time points .(2-10 hours), but is markedly decreased after 20 hours.
(Wang, et. al. , 1991) The later time points, those after 16 hours, of the CLP model are
similar to the high dose endotoxin model in this study in that they both represent a
hypodynamic model of sepsis. Hepatocellular dysfunction, tested by ICG clearance, was
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seen at both the early and later time points with a higher degree of dysfunction at 20
hours. (Wang, et. al., 1991) Since lidocaine in this study was distributed via the hepatic
artery, a decrease in blood flow could significantly alter the clearance of the drug from
the blood .
The concentration of MEGX was significantly higher in septic animals compared
to control and cimetidine, and cimetidine animals compared' to controls. During the early
time points all three groups have an increasing slope, but while the slopes of the
cimetidine and control groups level off at later time points, the MEGX levels of the
endotoxin group still increase at these later time points. It has been shown in the acute
and chronic endotoxic rat there is a decrease in renal blood flow. (Fish, et. al., 1986)
Endotoxin also results in impaired renal oxygenation and perfusion in the dog model,
which is due to central hypotension and the local effects of endotoxin on the kidney.
(Gullichsen, et. al., 1989) The decrease of renal blood flow, and the resultant renal
failure, may be a cause of the accumulation ofMEGX in the serum at the later time
points. These data seem rather anomalous when looked at in conjunction with the
lidocaine concentrations. A possible reason for the increased concentration of MEGX
could be due to liver cell dysfunction and the poor elimination of drug metabolites from
the blood.
During sepsis, hepatocellular dysfunction occurs within 2 hours (Wang, et. al.,
1995), as well as a reduction in bile flow. (Bolder, et. al., 1997) This loss of function
decreases the amount lidocaine met"ibolites being eliminated by the bile duct, and in
conjunction with poor renal perfusion, there could be an increase of lidocaine metabolites
in the serum in the endotoxic model. It has been recently shown in a severe ischemia-
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reperfusion injury rat model that the fluorescence immunoassay used in this experiment,
is not selective in detecting only MEGX, but also detects other lidocaine metabolites,
particularly the free, and conjugated forms of hydroxy-MEGX, which accumulated in the
plasma. (LeClercq, et. al., 1997) If renal perfusion and bile flow, the two main routes of
metabolite excretion, are lower during sepsis, there will be an accumulation of
metabolites in the rat. If septic rats have higher levels of lidocaine metabolites in their
serum due to accumulation the amounts will be higher than what is being generated at
that time. When analyzed, the immunoassay will detect all the MEGX and hydroxyMEGX generated and not excreted, resulting in higher values than control and
cimetidine.
Since levels ofMEGX were shown to be elevated during sepsis in our rat model,
we wanted to see if we could use a lidocaine:MEGX ratio as a marker for drug
metabolizing capabilities instead of just looking at the metabolite. AB was stated earlier,
lidocaine clearance was significantly lower in the endotoxin group, whereas MEGX
formation was higher. Ratios of serum levels of lidocaine:MEGX were significantly
different for all three groups at 15 minutes. Measurements at this point are more variable
than measurements of serum ratios taken at a time interval when the clearance and
metabolite might be reaching a steady state. In this experiment a steady state started to
occur between 45 and 60 minutes, and a ratio of parent to metabolite might make it
possible to assess the livers drug metabolizing capabilities, rather than at an earlier time
point. Elin, et. al. looked to see if there was a difference in parent: metabolite ratios using
lidocaine, as an assessment tool to determine liver function in patients with chronic viral
hepatitis but found no significant difference, which was not surprising since the
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differences in lidocaine and MEGX concentrations were not significantly different either.
(Elin, et. al., 1997) Therefore this is a novel approach that needs further examination in
various other types of disease states, as well as in hypodynamic sepsis, to validate its
usefulness.
The two sub-populations of the endotoxin group gained our interest. We
examined these two groups separately to see if there was any difference between those
rats that had a drop in blood pressure, compared to those that did not. Both groups had a
significantly lower clearance of lidocaine, compared to the control group, but were not
significant compared to each other. Although we did not see a significant effect, there is
the possibility that there is a significant difference between the shock and non-shock
animals, and a type II statistical error might have been committed with our small sample
size. Further experimentation would support the role that altered hemodynamics might
play in the elimination of lidocaine during septic shock.
MEGX concentrations between the two sub-populations were significantly higher
for the non-shock than shock group. This supports the idea previously mentioned in
regards to the hepatocellular dysfunction inhibiting bilary excretion of the metabolite
compounds. The renal blood flow in the non-shocked animals most likely is not changed,
so the accumulation of metabolite could possibly be due to a reduction in bile flow . This
would lead to an accumulation of MEGX and the free and conjugated forms of hydroxyMEGX, which could not be distinguished with the TDx immunoassay.
In conclusion, endotoxin produces many negative physiologic changes that are
seen systemically, in specific organs, and cellularly. Endotoxin can cause severe
hypotension. Endotoxin inhibits the P450 drug-metabolizing enzyme system, which is
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responsible for removing xenobiotics from the body non-toxically . The specific isoforms
which, are capable of metabolizing lidocaine, are inhibited by endotoxin. This inhibition
reduces the clearance of lidocaine from the serum in septic rats, and the systemic effects
led to an accumulation of lidocaine metabolites in the serum, which can possibly be
indistinguishable using the TDx analyzer. Due to these conflicting results, the ratio of
lidocaine:MEGX is being postulated as a possible tool determining drug metabolizing
capabilities during sepsis, but further validation is needed in this model of hypodynamic
sepsis.
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Appendix I
The metabolism of lidocaine by rat liver microsomes has been studied
extensively. (Nakamoto, et. al., 1997; Oda, et. al., 1989; Imaoka, et. al., 1990) Lidocaine
is N-deethylated to give monoethylglycinexylidide (MEGX), its major metabolite.
(Figure 9) This reaction is catalyzed by various P450 enzymes in the rat liver, but the
..

isoforms which have shown the highest turnover for MEGX formation are largely P450
2Bl, 2Cl 1, and 3A2. (Nakamoto, et. al., 1997; Oda, et. al., 1989; Imaoka, et. al., 1990)
Endotoxin administration has been shown to inhibit many P450 isoforms, specifically
P450 3A2, and 2Cll, (Sewer, et. al., 1996; Morgan, et. al., 1993) in rats, and 2Bl in mice
(Stanley, et. al., 1991 ), which are the same isoforms that metabolize lidocaine. In this
study we examined the effects of an acute, lethal dose of endotoxin on the metabolism of
lidocaine in isolated rat liver microsomes.
Male Sprague Dawley rats, ranging from 250-550g, were administered endotoxin,
cimetidine, or no treatment. Cimetidine, 80mg/kg, was injected IP, daily for three days
prior to surgery, was used as a positive control for inhibition of cytochrome P450.
(Levine, et. al., 1998) Endotoxin (E. Coli 026 :B6 LPS, lot #91608), 45.6 mg/kg, was
injected IP six hours before the liver was removed and homogenized.
Rats were sacrificed, and the front two lobes of the liver were excised. Livers
were weighed and homogenized 1:3 in phosphate buffered solution (PBS) containing
NaCl 136.9mM, KC! 2.2 mM, NaH2P04 8.1 mM, KH2P04 1.5 mM, pH 7.4. The
homogenates were centrifuged at 4°C for 20 minutes at 10,000 x g. Supernatant was
decanted off, and 5 mL of ice cold PBS was added. The supernatant was then centrifuged
in a Beckman Ultracentrifuge, using a 42.1 rotor, at 4°C for one hour at 35,000 x g. The
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supernatant was poured off and discarded . Fifteen mL of ice cold PBS was added , and
the microsomal pellet was vortexed away from the glycogen, and resuspended using a
glass homogenizer. The homogenate was centrifuged again, to reduce the amount of
hemoglobin, at 4°C for one hour at 35,000 x g. Supernatant was discarded, and the pellet
was resuspended in 7.0 mL of PBS . The microsomal solution was pipetted out into 1.0
mL aliquiots and frozen at -80°C. Total microsomal protein was determined by
bicinchoninic acid (BCA) assay. (Smith, et. al., 1985)
Microsomal solution, 50 µL, was incubated in 0.1 mol/L sodium phosphate
(NaPi) buffer, pH 7.4, in a final volume of 400 µL, in the presence of 4 mM reduced
nicotinamide adenine dicucleotide. Lidocaine was then added in a final concentration of
50 µM. The reaction was incubated at 37°C for 20 minutes and then stopped by the
addition of 10 µL of 70% perchloric acid. Denatured protein was removed by
centrifugation, and the supernatant was analyzed for lidocaine and MEGX by the TDx
analyzer. (Abbott laboratories)
There was no significant difference between the different treatment groups in the
amount of lidocaine consumed. The control group consumed 2.7 nmol of lidocaine,
while the endotoxin and cimetidine group consumed 3.3, and 2.9 nmol of lidocaine
respectively. There was no significant difference in MEGX formation between any of the
treatment groups. (Figure 10)
Lidocaine is metabolized by many P450 isoforms, but those that possess the
highest activity for the catalyzation of lidocaine to MEGX are 2C 11, and 3A2, in rat liver
microsomes. (Nakamoto, et. al., 1997) ln our experiment we found there was no
diffference between groups. We expected there to be a significant difference between the
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endotoxin and untreated groups, as well as between the cimetidine group and the
untreated group, in the amounts of lidocaine metabolized, and the amount of MEGX
formed . We had expected to see more lidocaine and Jess MEGX in the endotoxin groups
because all three of the isoenzymes responsible for lidocaine metabolism are inhibited by
endotoxin. (Morgan, 1990; Sewer, et. al., 1996) It has been shown in vivo and in the
perfused rat liver that lidocaine clearance is inhibited by cimetidine. (Bruck, et. al., 1990;
Fruncillo, et. al., 1983) This decrease in lidocaine clearance can be due to cimetidine
inhibition of P4502Cl 1, but not 3A2. (Levine, et. al., 1998) In this experiment, we
expected to see some difference between the control and the cimetidine groups in regards
to MEGX formation, and lidocaine elimination. The inhibition was expected to be less
than that seen with endotoxin because of cimetidines incomplete inhibition of all
lidocaine metabolizing P450 isoforms.
Previous studies have shown that MEGX formation was much greater than that
shown in this experiment. (Nakamoto, et. al. 1997; Oda, et. al. , 1989) Our values were
very minute, between 1-8 x 10-5 , while in other studies there was a 100 times greater
amount of MEGX formed . This comparison with other researchers results leans us to
believing the microsomes used in the experiment were not as active. The methodologies
used by these groups worked with microsomes stored in 250 mM sucrose. We stored our
isolated microsomoes in PBS, as described by Muller, et. al. All other procedures were
similar, leading us to believe it is this difference in the storage which led to the faulty
results. (Muller, et. al., 1996)
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Figure 9. Metabolic pathways of lidocaine. (Drawn from published data. Oda, et. al,
1989; Chandel, et. al , 1995)
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Figure 10. In vitro MEGX concentrations (ng/ug protein). 50 µM Lidocaine was added
to 50 µL of microsomes containing 50 µL PBS, 0. lM NaPi, and 2mM NADH, and
incubated at 37°C for 20 minutes. Assay was centrifuged and supernatant was analyzed
for MEGX concentration by flourescence immunoassay. Values represent pmoles of
MEGX formed per minute per µg protein.
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Appendix II
Infections in humans and animals are capable of altering the expression and
activity of the enzyme isoforms that make up the cytochrome P450 drug metabolizing
enzyme gene superfamily. There are at least 14 families and 26 sub-families which
belong to the P450 enzyme system in mammals. (Nelson, et. al., 1996) Many
xenobiotics as well as physiologically produced substrates are bioactivated or
biotransformed, or detoxified by this enzyme system, so the regulation of this system is
very important. Although there are many different genes, only a select few are
responsible for the metabolism of most drugs. In humans these isoforms are P450's 1A2,
2A6, 2C8, 2C9, 2Cl 1, and 3A4. (Spatzenegger, et. al., 1995) In rodents and other
mammals, there are homologous counterparts to these isoenzymes. (Imaoka, et. al, 1990)
Potential alterations in these enzymes as a result of an infection have the potential to
change serum levels of therapeutic compounds.
In a serious infection, like sepsis, there is an overwhelming inflammatory
response that occurs on the systemic level. This systemic inflammatory response is
correlated with the generation and release of various cytokines. (Jacobs, et. al., 1989)
These cytokines are capable of altering the hepatic metabolism of drugs through
suppression of the aforementioned P450 isoforms, making the understanding how these
cytokines alter P450 activity clinically relevant.
Endotoxin, or lipopolysaccharide (LPS), found on the cell wall of the gramnegative bacteria, is used as a model for bacterial sepsis. Endotoxin administration
causes activation of the inflammatory response system, which results in high
concentrations of cytokines released into the bloodstream. (Cannon, et. al, 1990; Hack, et.
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al, 1989) In the endotoxin model, these high concentrations of cytokines, as well as the
LPS itself, centralize near the hepatocyte. (Billiar, et. al, 1992)
The release of tumor necrosis factor a (TNF-a) from macrophages is the primary
step in response to LPS administration in animals. (Lowry, 1993) TNF-a then upregulates the release of itself and interleukin- I (IL-1 ), which in conjunction with TNF-a,
stimulates the release of interleukin-6 (IL-6), as well as many other mediators of the
inflammatory system. Since the liver has its own macrophages, the Kupffer cells,
endotoxin can act directly in the liver to generate the immune response, releasing
cytokines directly at the liver. Results of this are the high levels ofliver localized
cytokines. (Billiar, et. al. 1992)
Overall administration ofLPS has effects on the activity and regulation of the
P450 system. LPS causes decreases in P450 protein and mRNA expression in rat
hepatocytes. (Carlson, et. al, 1996; Sewer, et. al., 1997) Although the effect can be
through the endotoxin acting directly on these hepatocytes to cause these changes, the
activation of the Kupffer cells, and subsequent release of cytokines, may also mediate
these changes. Since LPS causes a rise in cytokine levels, and these cytokines play a role
in the inflammatory response, the effects of certain cytokines on P450 regulation have
been described.
Several studies have described the effects of independent administration of TNFa, IL-1 , and IL-6 on drug metabolism and P450 levels have been looked at. In the rat

..
model, total levels of P450 are suppressed by TNF-a, and IL-1. (Pous, et. al., 1990;
Wright, et. al., 1991; Nadin, et. al., 1995) Rats treated with TNF-a had decreased levels
of activity, mRNA expression, and protein content of P450's 2C 11 and 3A2 after one and
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three days of treatments. (Nadin, et. al., 1995) Further evidence supporting the
involvement of TNF-a in the suppression of some P450 isoforms came from the
administration of pentoxifylline to rats. Pentoxifylline blocks TNF-a formation in
response to LPS. When administered to rats given LPS, the LPS induced suppression of
2El and 3A2 in rat liver was blocked. (Monshouwer, et. al., 1996)
Administration of IL-1 is also selective for inhibitio·n of various isoforms of P450.
A single dose of IL-1 to rats suppressed the total hepatic P450 content as well as the
metabolizing activities of many xenobiotics, 24 hours after administration. (Kurokohchi,
et. al., 1992) Daily doses of IL-la elicited a reduction of activity, but not expression of
P450 3A2, 2Cl 1, and lAl in male rats. (Ferrari, et. al., 1993) Decreases in the
expression of 2C 11 and 3 A2 after two IL-1 injections were also seen in the male rat liver
after 24 hours. (Morgan, et. al., 1994)
IL-6 also can alter the activity and expression of P450. (Wright, et. al, 1991 ;
Morgan, et. al. 1994; Chen et. al., 1992) Suppression of the protein and mRNA of P450
2Cl 1, and the mRNA of 2El , was seen after three injections of IL-6. (Morgan, et. al.
1994) There were no alterations in the levels of P450 3A2 or 2El mRNA or protein after
24 hours . (Morgan, et. al. 1994)
The effect cytokines have on cells, and the regulation and activity of intracellular
processes, are through receptor activated second messengers. The response each of these
cytokines previously mentioned has on hepatocytes is played out through these second
messengers. One type of second m.essenger in liver cells are sphingolipids. Ceramide, a
product of the hydrolysis of sphingomyelin, by sphingomyelinase, is thought to act as a
second messenger in many cell types. lt has been shown that IL-1 and TNF-a activate
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sphingomyelinase to produce ceramide. (Hannun, et. al. , 1994) Incubation of hepatocytes
with either sphingomyelinase or a short chain ceramide, (C 2 -ceramide) has shown
suppression of 2C 11, mimicing the effects of IL-1. (Chen, et. al., 1995) This suggests
that sphingolipids can act in determining the expression of hepatic P450 genes. The
question still remains as to whether it is ceramide carrying out the effects in the cell, or if
it is the products, sphingosine and sphingosine-1-phosphate, of ceramide metabolism.
The metabolites of ceramide have been researched, and it has been shown that at doses of
IL-1, capable of suppressing 2C 11, and maximize the activity of sphingomyelinase,
ceramide is barely detectable. (Chen, et. al., 1995)
Another second messenger in cells is nitric oxide (NO). NO is a product of nitric
oxide synthase, which forms NO from arginine. There are two forms of nitric oxide
synthase. The one relevant to LPS, is the inducible form that is found in macrophages
and hepatocytes upon an inflammatory stimulation. (Bredt, et. al., 1994; Morris, et. al.,
1994) NO is capable of binding to any heme containing protein, and cytochrome P450 is
no exception. Upon binding to P450, the catalytic activity is altered, and the inhibition is
only partially reversible. (Wink, et. al. , 1993) Several studies have investigated the role
of P450 inhibition by nitric oxide after LPS administration. The addition of a nitric oxide
synthase inhibitor to the drinking water of rats four days before LPS administration
partially prevented a decline of2Bl and 2B2 activity, and mRNA, seen in endotoxemic
animals pretreated with phenobarbital to induce the concentrations of 2B 1 and 2B2.
(Khatsenko, et. al. , 1993 ; Khatsenko, et. al. , 1994)) It was postulated from these
experiments that the decrease in P450 catalytic activity is due to the increase of NO in the
cell, and this increase of NO also might be a contributing factor to the degradation of the

50

P4 50 enzymes. (Khatsenko, et. al., 1993) Muller, et. al. also showed that the the
administration of either two different nitric oxide synthase inhibitors in normal or
phenobarbital treated rats inhibited the decreases seen in the LPS generated decline of
P450 content, as well as ethylmorphine N-demethylase, and the metabolism of
midazolam. (Muller, et. al, 1996) In rats, the enzymes involved in the metabolism of
ethyl morphine are P4502B1, 2C6, 2Cl 1, and 3A2, so many of the isoforms responsible
for drug metabolism are inhibited by NO .

In summary, LPS causes a widespread systemic inflammatory response. This
response is mediated by various cytokines, and the effects of these cytokines on different
cell types is degradative. It has been shown in hepatocytes, endotoxin, can interact and
alter the expression and activity of the P450 system. Other studies have shown
corraborative evidence that the mediators IL-1, IL-6, and TNF-a, all have the ability to
suppress different P450 isoforms important to the metabolism of drugs. The formation of
second messengers from receptor mediated binding of these cytokines has also been
investigated. Increased levels of ceramides have been shown to inhibit P450 expression.
Nitric oxide has also been suggested as a culprit in the inhibtion of catalytic activity of
the P450 enzymes. In closing, although much work has been done to examine the
mechanisms of regulation of the P450 system during endotoxemia, there is much more
research of unanswered questions to be done.
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Appendix III

Conclusions and Future Investigations

Conclusions:

1.) An LD 100 dose of endotoxin causes severe hypotension in rats after eight hours.
2.) Lidocaine clearance is decreased in this rat model of endotoxin induced septic shock,
compared to controls, after 25 minutes of lidocaine administration.
3.) Increased concentrations of the metabolite MEGX was seen in septic rats, compared
to controls, 120 minutes after administration of lidocaine.
4.) Levels of MEGX increased during septic shock, and a definitive reason for this
increase is still unknown, since the TDx assay for MEGX also detects hydroxyMEGX (LeClercq, et. al. , 1997). The lidocaine:MEGX ratio could be a useful
indicator of drug metabolism inhibition, but further validation is needed in a model
where accurate concentrations ofMEGX have been determined .

Future Investigations:

1.) It has been shown that the TDx assay for MEGX is also sensitive to hydroxy-MEGX.
(LeClercq, et. al. , 1997) Examination of the serum concentrations of MEGX and
hydroxy-MEGX using high performance liquid chromatography to examine the
concentrations of each of these-t-wo metabolites is needed to determine the actual
concentrations of metabolites.
2.) Microsomal amidases are capable of rapidly hydrolyzing MEGX. (Hollunger, et. al.,
1960) Investigation to see whether these amidases are inhibited by endotoxin, would
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add further explanation to the increase of serum MEGX levels seen in our septic
model.
3 .) Reduction in bile flow has been shown in endotoxic rats. (Bolder, et. al., 1997) Since
bile flow is one possible route for lidocaine metabolite excretion, investigation of the
role this reduction in bile flow has on the increased levels of MEGX in the serum
seen in the endotoxic model is needed.
4.) Since lidocaine is a high extraction compound, blood pressure plays an important role
on its clearance. Examination of the extent to which severe hypotension alters the
clearance oflidocaine, and the excretion of MEGX, is necessary.

53

Bibliography
Bennett, P., Aarons, L., Bending, M., Steiner, J., Rowland, M. (1982) Pharmacokinetics
of lidocaine and its deethylated metabolite: dose and time-dependency studies in man.

Journal of Pharmacokinetics and Biopharmaceutics 10(3):265-281.

Billiar, T., Curran, R., Williams, D., Kispert, P. (1992) Liver nonparenchymal cells are
stimulated to provide IL-6 for induction of the hepatic acute phase response in
endotoxemia but not in remotee localized inflammation. Archives of Surgery 127(1):3136.

Bolder, U., Ton-Nu, H., Schteingart, C., Frick, E., Hofman, A. (1997) Hepatocyte
transport of bile acids and organic anions in endotoxemic rats; impaired uptake and
secretion. Gastroenterology 112(1):214-225 .

Bredt, D., Snyder, S. (1994) Nitric oxide: a physiologic messenger molecule. Annual

Reviews of Biochemistry 63: 175-195 .

Bruck, R., Krepel, Z., Bar-Meir, S. (1990) Cimetidine and Orneprazole have different
effects on hepatic extraction of lidocaine in rats. Gastroenterology 99:857-859.

Burdelski, M., Oellerich, M., Larnesch, P. (1987) Evaluation of Quantitative liver
function tests in liver donors. Transplantation Proceedings 19:3638-39.

54

Burderlski, M., Oellerich, M., Raude, E. (1988) A novel approach to assessment of liver
function in donors. Transplantation Proceedings (Supplement 1):591-593

Cannon, J., Tompkins, R., Gelfand, J. , Michie, H ., Stanford, G ., van der Meer, J., Endres,
S., Lonnemann, G ., Corsetti, 1., Chernow, B. (1990) Circulating interleukin-I and tumor
necrosis factor in septic shock and experimental endotoxin fever. Journal of Infectious

Disease 161:79-84.

Carlson, T ., Billings, R. (1996) Role of nitric oxide in the cytokine mediated regulation
of cytochrome P450 . Molecular Pharmacology 49(5):796-801 .

Chandel, B., Shapiro, M., Kurtz, M., Rana, W. , Matthews, M ., Jellinek, M. , Baue, A
(1995) MEGX: A novel in vivo test to measure early hepatic dysfunction after
hypovolemic shock. Shock 3(1) 51-53 .

Chen, Y. , Florentin, I. , Batt, A , Ferrari, L. , Giraud, 1. , Moachon, L. (1992) Effects ofll6 on cytochrome P450 dependent mixed function oxidases in the rat. Biochemical

Pharmacology 44(1) : 137-148 .

Chen, J., Nikolova-Karakashian, M., Merrill, A. , Morgan, E . (1995) Regulation of
cytochrome P450 2C 11 gene expression by [L-1, sphingomyelin hydrolysis, and
ceramides in rat hepatocytes. Journal of Biological Chemistry 270(42): 25233-25238.

55

Dedichen, H. (1972) Hemodynamic changes in experimental endotoxin shock. Acta

Chirurgica Scandinavica 138 :215-225

Elin, R., Fried, M., Sampson, M., Ruddel, M., Kleiner, D., Dibisceglie, A. (1997)
Assessment of monoethylglycinexylidide as measure of liver function for patients with
chronic viral hepatitis. Clinical Chemistry 43(10): 1952-19.57.

Ferrari, L., Herber, R., Batt, A., Siest, G. (1993) Biochemical Pharmacology 45:2269.
Fish, R.E., Lang, C.H., Spitzer, J.A. (1986) Regional blood flow during continuos lowdose endotoxin infusion. Circulatory Shock 18:267-275.

Fruncillo, R., Di Gregorio, J., Soll, A. (1983) Effect of cimetidine on the
pharmacokinetics of quinidine and lidocaine in the rat. Journal of Pharmaceutical

Sciences 72(7):826-828.

Gullichsen, E., Nelimarkka, 0., Halikola, L., Niinikoski, J. (1989) Renal oxygenation in
endotoxin shock in dogs. Critical Care Medicine 17(6) 547-550.

Hack, E., DeGroot, E., Richelle, J. (1989) Increased plasma levels ofIL-6 in sepsis.

Blood 74: 1704-1710.

Hannun, Y. (1994) The sphingomyelin cycle and the second messenger function of
ceramide. Journal of Biological Chemistry 269(5):3125-3128 .

56

Hollunger, G. (1960) On the metabolism of lidocaine. II. The biotransformation of
lidocaine. Acta Pharmacologia et Toxicologia 17:365-373.

Imaoka, S., Enomoto, K., Oda, Y., Asada, A.. Fujimori, M., Shimada, T., Fujita, S.,
Guengerich, P ., Funae, Y. (1990) Lidocaine metabolism by human cytochrome P450s
purified from hepatic microsomes: comparison of those with rat hepatic cytochrome
P450s. The Journal of Pharmacology and Experimental Therapeutics, 255(3) 1385-1391.

Ishikawa, M., Sasaki, K., Nishimura, K., Takayanagi, Y., Sasaki, K. (1991) Endotoxin
and inflammation induced depression of the hepatic drug metabolism in rats. Japanese

Journal of Pharmacology 55 : 551-554.

Jacobs, R., Trubor, D. (1989) Immune cellular interactions during sepsis and septic
injury. Critical Care Medicine 5(1) :9-26.

Keeler, R., Barrientos, A., Lee, K. (1981) Circulatory effects of acute or chronic
endotoxemia in rats. Canadian Journal of Physiology 59:204-208.

Keenaghan, J., Boyes, R. (1972) The tissue distribution, metabolism, and excretion of
l idocaine in rats, guinea pigs, dogs; ·and man . .Journal of Pharmacology and

Experimental Therapeutics 180(2):454-463 .

57

Khatsenko, 0 ., Gross, S., Rifkind, A. , Vane, J. ( 1993) Nitric oxide is a mediator of the
decrease in cytochrome P450 dependent metabolism caused by immunostimulants.

Proceedings of the National Academy of Sciences 90(23) : 11147-11151 .

Khatsenko, 0 ., Boobis, A., Gross, S., Vane, J. (1994) Federation ofAmerican Societies

for Experimental Biology Journal 8:X56 .

Kurokohchi, K., Yoneyama, H., Matsuo, Y. , Nishioka, M ., Ichikawa, Y. (1992) Effects of
IL-6 on the activities and gene expressions of the cytochrome P450IID subfamily.

Biochemical Pharmacology 44(8):1669-1674.

Leclercq, I., Saliez, A. , Wallemacq, P.E .. , Horsmans, Y. , Lambotte, L. (1997) The
monoethylglycinexylidide test does not correctly evaluate lidocaine metabolism after
ischemic liver injury in the rat. Hepatology 26(5) 1182-1188.

Levine, M., Law, E ., Bandiera, S., Chang., T. , Belward, G. (1998) In vivo cimetidine
inhibits hepatic CYP2C6 and CYP2C 11 but not CYP 1A1 in adult male rats. Journal of

Pharmacology and Experimental Therapeutics 284(2):493-499.

Lowry, S. (1993) Cytokine mediators of immunity and inflammation. Archives of Surgery
128(11) :1235-1241.

58

Monshouwer, M., Mclellan, R. , Delaporte, E., Witkamp, R., Van Miert A., Renton, K.
( 1996) Differential effect of pentoxifylline on the lipopolysaccharide induced down
regulation of cytochrome P450 . Biochemical Pharmacology 52(8) : 1195-1200.

Morgan, E.T. ( 1989) Suppression of constitutive cytochrome P450 gene expression in
livers of rats undergoing an acute phase response to endotoxin. Molecular Pharmacology
36:699-707 .

Morgan, E.T. ( 1993) Down-regulation of multiple cytochrome P450 gene products by
inflammatory mediators in vivo: independence from the hypothalamo-pituitary axis.

Biochemical Pharmacology 45(2):415-419.

Morgan, E., Thomas, K., Swanson, R., Vales, T., Hwang, J., Wright, K. (1994) Selective
suppression of cytochrome P450 gene expression by IL-1 and IL-6 in rat liver.

Biochimica Biophysica Acta 1219(2):475-483 .

Morgan, E. (1997) Regulation of cytochromes P450 during infection and inflammation.

Drug Metabolism Reviews 29(4) : 1129-1188.

Morris, S., Billiar, T. ( 1994) New insights into the regulation of inducible nitric oxide.

American Journal of Physiology 266(6 Pt. l):E829-E839.

59

Muller, C., Scierka, A., Stiller, R., Kim, Y., Cook, D ., Lancaster, J., Bulfington, C.
( l 996) Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by
endotoxin. Anesthesiology 84: 143 5-1442.

Nadin, L., Butler, A., Farrell, G., Murray, M. (1995) Pretranslational down-regulation of
cytochromes P450 2Cl l and 3A2 in male rat liver by tumor necrosis factor alpha.

Gastroenterology l 09(1):198-205.

Nakamoto, T., Oda, Y., Imaoka, S., Funae, Y., Fujimori, M. (1996) Effect of
phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3hydroxylidocaine in the rat: correlation of P450 isoform levels. Drug Metabolism and

Disposition 25(3) 296-300.

Nelson, D., Koymans, L., Kamataki, T ., Stegeman, J. , Feyereisen, R., Waxman, D.,
Waterman, M ., Gotoh, 0 ., Coon, M., Estabrook, R ., Gunsalus, I., Nebert, D. (1996) P450
superfamily: update on new sequences, genes, mapping, accession numbers and
nomenclature. Pharmacogenetics 6( l ): 1-42.

Nyberg, G., Karlen, B., Hedlund, I., Grundin, R., von Bahr, C. (1977) Extraction and
metabolism of lidocaine in rat liver. Acta Pharmacology and Toxicology 40(2) :337-346.

60

Oda, Y., Imaoka, S., Nakahira, Y., Asada, A., Fujimori, M., Fujita, S., Funae, Y. (1989)
Metabolism of lidocaine by purified rat liver microsomal cytochrome P450 isozymes.

Biochemical Pharmacology 38(24):4439-4444.

Oellerich, M., Raude, E. , Burderlski, M. (1987) Monoethylglycinexylidide formation
kinetics: a novel approach to assasment of liver function. Journal of Clinical Chemistry

and Clinical Biochemistry 25 :845-853 .

Oellerich, M., Ringe, B., Gubernatis, G ., Pichlmayr, R., Burdelski, M., Lamesch, P.,
Bunzendahl, H., Herrmann, H. (1989) Lignocaine metabolite formation as a measure of
pre-transplant liver function. The !Ancel March 25 640-642.

Oellrich, M ., Burdelski, M., Lautz, H., Schulz, M., Schmidt, F ., Herrmann, H. (1990)
Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis.

Therapeutic Drug Monitoring 12:219-226.

Parillo, J. (1993) Pathogenic mechanisms of septic shock. The New England Journal of

Medicine 328(20) :1471-1477.

Pous, C., Giroud, J., Damais, C., Raichvarg, D., Chauvelot-Moachon, L. (1990) Effect of
..
recombinant human interleukin- I beta and tumor necrosis factor alpha on liver
cytochrome P450 and serum alpha- I-acid glycoprotein in the rat. Drug Metabolism and

Disposition 18(4):467-470.

61

Schroeder, T., Gremse, D., Mansour, M ., Theurling, A. , Brunson, M ., Ryckman, F.,
Suchy, F., Penn, I., Alexander, J. , Pesce, A., First, M ., Balistreri, W . (1989)

Transplantation Proceedings 21(1) 2299-2301.

Sewer, M ., Koop, D., Morgan, E. (1996) Endotoxemia in rats is associated with induction
of the P4504Asubfamily and suppression of several other forms of cytochrome P450 .

Drug Metabolism and Disposition 24(4) 401-407.

Sewer, M., Morgan, E . (1997) Nitric oxide independent suppression of P4502Cl1
expression by interleukin- I beta and endotoxin in primary rat hepatocytes. Biochemical

Pharmacology 54(6):729-737.

Shedlofsky, S., Israel, B., McClain, C., Hill, D., Blouin, R . (1994) Endotoxin
administration to humans inhibits hepatic cytochrome P450 mediated drug metabolism.

The Journal of Clinical Investigation 94 :2209-2214.

Smith, P., Krohn, R ., Hermanson, G., Mallia, A., Gartner, F., Provenzano, M ., Fujimoto,
E., Goeke, N., Olson, B ., Klenk, D. (1985) Measurement of protein using bicinchoninic
acid. Analytical Biochemistry 150:76-85 .

Spatzenegger, M., Jaeger, W. (1995) Clinical importance of hepatic cytochrome P450 in
drug metabolism. Drug Metabolism Reviews 27(3) :397-417.

62

Stanley, L. Adams, 0., Lindsay, R., Meehan, R., Liao, W., Wolf, C . (1988) Potentiation
and suppression of mouse liver cytochrome P450 isozymes during the acute phase
response induced by bacterial endotoxin . European Journal of Biochemistry 174:31-36.

Suffredini, A., Fromm, R ., Parker, M ., Brenner, M., Kovacs, J., Wesley, R ., Parillo, 1.
(1989) The cardiovascular response of normal humans to the administration of endotoxin.

Tne New England Journal of Medicine, 321(5) 280-287.

Wang, P., Ba, Z ., Chaudry, I. (1991) Hepatic extraction ofindocyanine green is
depressed early in sepsis despite increased hepatic blood flow and cardiac output.

Archives of Surgery 126:219-224 .

Wang, P., Ba, Z., Chaudry, I. (1995) Hepatocellular dysfunction occurs earlier than th
eonset ofhyperdynamic circulation during sepsis. Shock 3(1) 21-26 .

Wink, D ., Osawa, Y. , Darbyshire, J., Jones, C., Eshenaur, S., Nims, R. (1993) Inhibition
of cytochromes P450 by nitric oxide and a nitric oxide releasing agent. Archives of

Biochemistry and Biophysics 300(1) : 115-123 .

Wright K., Morgan, E. (1991) Regulation of cytochrome P4502Cl2 expression by
interleukin-I, interleukin-6, and dexamethasone. Molecular Pharmacology 39:468-474.

63

Zito, R., Reid, P. (1978) Lidocaine kinetics predicted by indocyanine green clearance.

The New England Journal of Medicine 298(21) :1160-1163.

64

